Hospital Ampang, Department of Obstetrics & Gynaecology, Gynaecologic Oncology Unit, Selangor, Malaysia.
Institut Kanser Negara, Department of Gynaecologic Oncology, Putrajaya, Malaysia.
Med J Malaysia. 2024 Sep;79(5):547-555.
Epithelial ovarian cancer (EOC) is the fourth most common malignancy among Malaysian women. This study aims to evaluate the outcomes of EOC, fallopian tube cancer and primary peritoneal serous carcinoma (PPSC) between a centre managed by both clinical oncologists and gynaecologic oncologists, Institut Kanser Negara (IKN) and a centre managed solely by gynaecologic oncologists, Hospital Ampang (HA).
This retrospective cohort study involved data review of all the newly diagnosed patients with EOC, fallopian tube cancer and PPSC who received treatment in IKN and HA from January 2015 to December 2019, with follow-up continuing until December 2022. The primary outcome is overall survival (OS) and the secondary outcome is progression free survival (PFS) rates; estimated using the Kaplan-Meier method and compared using the logrank test. Another secondary outcome is to determine the prognostic factors affecting the OS of patients from these two cohorts using Cox regression analysis.
A total of 256 patients from both centres were recruited (106 and 150 patients from IKN and HA respectively) and at the time of diagnosis, more than half of the patients were diagnosed with advanced stage disease (67.5% and 62% from IKN and HA respectively). The median OS for patients with EOC was significantly longer for HA compared to IKN (69 months vs 39 months, p < 0.042). There was no significant difference in the median PFS for both centres. Furthermore, when the comparison was made based on the disease staging, there was no difference in the median OS and median PFS. Multivariate analysis identified that patients aged between 41 and 60 years (Hazard ratio [HR]: 2.83; 95% CI: 1.11, 7.25, p = 0.030), patients with medical illness (HR 1.51; 95% CI: 1.04, 2.21, p = 0.033), patients with advanced-stage disease (HR: 3.63; 95% CI: 2.20, 6.00, p < 0.001) and patients with ECOG ≥ 1 (HR: 2.00; 95%CI: 1.38, 2.91, p < 0.001) as independent risk factors for adverse outcome. Meanwhile, optimal surgery is found to be a protective factor (HR 0.60; 95% CI: 0.41, 0.89, p = 0.011). Patients with optimal surgery had reduced the risk of adverse outcome.
Our findings confirmed that the median OS was significantly longer for patients with EOC in HA compared to IKN. However, there was no significant difference in the median OS based on the disease staging; therefore, we could not establish the non-inferiority outcome between the two centres. Furthermore, there was no significant difference in median PFS for both centres. This could be due to small sample size to be able to detect any difference. In addition, it could also be contributed by the different treatment options available and unequal volume of patients treated in both centres. Thus, further study with larger sample size and longer time period is needed to provide better guidance and treatments for the patients.
上皮性卵巢癌(EOC)是马来西亚女性中第四常见的恶性肿瘤。本研究旨在评估由临床肿瘤学家和妇科肿瘤学家共同管理的国家癌症中心(IKN)和仅由妇科肿瘤学家管理的安邦医院(HA)治疗的 EOC、输卵管癌和原发性腹膜浆液性癌(PPSC)患者的结局。
本回顾性队列研究对 2015 年 1 月至 2019 年 12 月期间在 IKN 和 HA 接受治疗的新诊断为 EOC、输卵管癌和 PPSC 的所有患者的数据进行了回顾,随访持续至 2022 年 12 月。主要结局是总生存期(OS),次要结局是无进展生存期(PFS)率;使用 Kaplan-Meier 方法估计,并使用对数秩检验进行比较。另一个次要结局是使用 Cox 回归分析确定来自这两个队列的患者 OS 的预后因素。
共有来自两个中心的 256 名患者入选(IKN 和 HA 分别为 106 名和 150 名患者),在诊断时,超过一半的患者被诊断为晚期疾病(IKN 和 HA 分别为 67.5%和 62%)。HA 组患者的中位 OS 明显长于 IKN 组(69 个月 vs IKN 组 39 个月,p<0.042)。两个中心的中位 PFS 无显著差异。此外,根据疾病分期进行比较时,中位 OS 和中位 PFS 无差异。多变量分析确定年龄在 41 至 60 岁之间的患者(风险比[HR]:2.83;95%CI:1.11,7.25,p=0.030)、患有内科疾病的患者(HR 1.51;95%CI:1.04,2.21,p=0.033)、晚期疾病患者(HR:3.63;95%CI:2.20,6.00,p<0.001)和 ECOG 评分为≥1 的患者(HR:2.00;95%CI:1.38,2.91,p<0.001)是不良预后的独立危险因素。同时,发现最佳手术是保护因素(HR 0.60;95%CI:0.41,0.89,p=0.011)。最佳手术的患者降低了不良预后的风险。
我们的研究结果证实,HA 组 EOC 患者的中位 OS 明显长于 IKN 组。然而,根据疾病分期,中位 OS 无显著差异;因此,我们无法确定两个中心之间的非劣效性结局。此外,两个中心的中位 PFS 无显著差异。这可能是由于样本量小,无法检测到任何差异。此外,这也可能是由于两个中心提供的治疗选择不同,以及治疗的患者数量不均等所致。因此,需要进行更大样本量和更长时间的进一步研究,为患者提供更好的指导和治疗。